A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19 |
Terminated |
Favipiravir |
3 |
RC20/174/R |
NGHA-R |
A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. |
Rejected |
Everolimus + Exemestane VS. Everolimus VS. Capecitabine |
2 |
CRAD001Y2201 |
KFSH & RC-R |
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy |
Ongoing |
Ofatumumab |
3b |
COMB157G23101 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS |
Completed |
Emicizumab |
3 |
MO39129 |
KFSH & RC-R |
A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer |
Ongoing |
abemaciclib |
3 |
I3Y-MC-JPCF |
KFMC |
A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) |
Completed |
Deferasirox dispersible tablet / Defearisox film-coated tablet |
2 |
CICL670F2201 |
KKUH |
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease |
Ongoing |
ombitasvir \ paritaprevir \ ritonavir |
3 |
Version 1.3.1 |
NGHA-J |
A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination |
Completed |
Bevacizumab |
3 |
ML18147 |
KFSH |
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation |
Ongoing |
Acalabrutinib |
3 |
D8221C00001 |
KFSH |
A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Completed |
Trastuzumab & Pertuzumab |
2 |
MO40628 |
KFSH & KFMC |